ArticleScientific reports2018

Preclinical Development of a Novel, Orally-Administered Anti-Tumour Necrosis Factor Domain Antibody for the Treatment of Inflammatory Bowel Disease.

J Scott Crowe et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.